We analyzed mutational data from 983 adult patients with TP53-mutant AML (216 from the Alliance for Clinical Trials in Oncology [referred to herein as Alliance]), the Beat AML program (10), and Rodriguez-Meira et al. (11) datasets, 99 from the University of Chicago, and 668 from American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) (12) to identify genetic alterations coexisting with TP53 mutations in AML. This evidence concerns the gene TP53 and acute myeloid leukemia.